Argenx

This study aimed to check the long-term safety of the drug efgartigimod in adults with primary Sjögren's syndrome. It included 24 participants who had already finished a previous efgartigimod trial and chose to continue treatment. The main goal was to monitor for side effects ove…

This study tested the long-term safety and effectiveness of a drug called efgartigimod for adults with primary immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, increasing bleeding risk. Over 100 patients received intravenous infusions for up t…

This study tested the long-term safety and effectiveness of a medication called efgartigimod, given as an injection under the skin, for people with generalized myasthenia gravis (gMG). It involved 184 adults who had previously benefited from the treatment in earlier studies. The …

This study tested whether giving a medication called efgartigimod continuously or in cycles works better for people with generalized myasthenia gravis, a condition that causes muscle weakness. The trial involved 69 adults who received the medication for up to 138 weeks. Researche…

This study tested whether adding an intravenous drug called efgartigimod to standard treatment could better control lupus nephritis, a serious kidney complication of lupus. It involved 73 Chinese adults with active kidney inflammation from lupus. The main goal was to see if the d…

This study tested whether efgartigimod injections could help adults with moderate to severe bullous pemphigoid, a rare autoimmune disease that causes painful skin blisters. Researchers compared the injection against a placebo in 98 participants to see if it could control disease …

This was an early safety study to see if a new drug called ARGX-109 is safe for people and how it moves through the body. It involved 40 healthy adults who received a single injection. The main goal was to check for side effects and measure drug levels in the blood over about 20 …